Drug Profile

HC 5404

Alternative Names: HC-5404; HC-5404-FU; PERK inhibitor - HiberCell

Latest Information Update: 10 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator HiberCell
Class Antineoplastics; Small molecules
Mechanism of Action EIF-2 kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Breast cancer; Gastric cancer; Renal cell carcinoma; Small cell lung cancer

Most Recent Events

04 Nov 2025 HiberCell and AVEO Oncology agree to co-develop HC 5404 alone and in combination with Tivozanib
17 Dec 2024 Chemical structure information added.
31 May 2024 Adverse events, efficacy and pharmacokinetics data from a phase-I trial in Solid tumours presented at the presented at the 60^th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com